Mar 15,2018

Incyte Targeted Therapy and Immuno-Oncology Portfolio to be Featured in 15 Abstracts at the AACR Annual Meeting 2018

Incyte Corporation (Nasdaq:INCY)announces that 15 abstracts from its research and development portfolio will be presented at the upcoming 2018 American Association for Cancer Research (AACR) annual meeting in Chicago, Illinois from April 14-18, 2018. These abstracts include the first pre-clinical data from the Company’s recently announced AXL/MER, TIM-3 and LAG-3 antibody programs in patients with advanced solid tumors.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Mar 23,2018

Voluntis and Roche Pharma France reinvent cancer patient support with digital therapeutics

Today, Voluntis and Roche Pharma France announced that important milestones have been reached in the development of ZEMY, a digital therapeutic developed by Roche Pharma France in partnership with Voluntis since 2015. ZEMY aims to improve care support for breast cancer patients. Its co-construction with various stakeholders (patients, healthcare professionals, etc.) has been critical in developing its medical algorithms and validating its ease of use. A multi-center clinical study has been initiated to evaluate adherence to the ZEMY solution as well as potential improvement in patients’ quality of life. Voluntis and Roche will seek regulatory clearance for this innovative software medical device.

PRODUCT

#dtx

View Analyst & Ambassador Comments
Go to original news
Feb 08,2018

New App Specifically for Colorectal Cancer Patients

Living with cancer can be isolating, and finding the right resource to connect with others in the same situation can be tough. But one app is aiming to make the process easier for patients with its new social media platform. This week, Belong, a social media app designed for cancer patients, announced that it will be partnering up with Toronto-based advocacy group Colorectal Cancer Canada (CCC) to develop a new platform specifically for CCC members. “This partnership enhances our vision to support patients and their loved ones while easing their concerns as they cope with a challenging disease,” Eliran Malki, cofounder and CEO of Belong, said in a statement.

PRODUCT

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 12,2018

Cancer-Fighting Nanorobots Programmed to Seek and Destroy Tumors

In a major advancement in nanomedicine, Arizona State University (ASU) scientists, in collaboration with researchers from the National Center for Nanoscience and Technology (NCNST), of the Chinese Academy of Sciences, have successfully programmed nanorobots to shrink tumors by cutting off their blood supply

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 01,2018

Roche to Acquire Flatiron Health to Accelerate Industry-Wide Development and Delivery of Breakthrough Medicines for Patients with Cancer

Roche (SIX: RO, ROG; OTCQX: RHHBY) and Flatiron Health, Inc. announced today that the two partners have signed a definitive agreement under which Roche will acquire all shares of Flatiron Health, following on from an existing equity stake of 12.6%. The transaction is expected to close in the first half of 2018. Under the terms of the agreement, Roche will make a payment of USD 1.9 billion to Flatiron Health on a fully diluted basis, subject to certain adjustments.

COLLABORATION MERGERS & ACQUISITION

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Feb 28,2018

Incyte Supports the Myeloproliferative Neoplasm Community in Honor of Rare Disease Day 2018

Incyte Corporation (Nasdaq:INCY) joins the National Organization for Rare Disorders (NORD), the European Organization for Rare Diseases (EURORDIS), and other rare disease health organizations and advocates in recognizing Rare Disease Day 2018.

View Analyst & Ambassador Comments
Go to original news
Jan 29,2018

Astellas to Present New Oncology Data at the 2018 ASCO Genitourinary Cancers (GU) Symposium

Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) today announced new data to be presented at the 2018 Genitourinary Cancers Symposium of the American Society of Clinical Oncology (ASCO GU) taking place on February 8-10 in San Francisco.

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Dec 05,2018

How Can Dermatology EMR Systems Optimize Patient-Doctor Communication?

Dermatology EMR systems are the primary technological platform doctors utilize to handle patient information. Ongoing developments in this field have allowed for the improved management and optimization of data access and storage. However, streamlined patient-doctor communication can still be challenging to achieve in spite of its intrinsic importance. This article looks to review the current advancements in modern dermatology EMR systems and what features they offer to support efficient communication for best dermatology practices.

#platform

View Analyst & Ambassador Comments
Go to original news
Dec 14,2018

The Cost-Benefits Of Teledermoscopy: Part 1

Teledermatology (with a focus in dermoscopy) is becoming a widely-cited solution for lowering healthcare costs while reducing patient wait times. How accurate is this statement? The following article compares two studies which focus on the financial feasibility of providing teledermoscopy services to patients as an e-triage solution.

#telehealth

View Analyst & Ambassador Comments
Go to original news
Dec 19,2018

Streamlined Pathology Workflows For Improved Patient Services In Dermatology

Dermatology services represent a multifaceted process, where professionals from several disciplines become involved in providing a final diagnosis. However, a multidisciplinary approach can become a substantial barrier if communication is not exercised correctly. This article will discuss the advantages of DermEngine for improved patient care through the eyes of an experienced dermatologist who is also a subscriber of the platform.

PRODUCT

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY